Add-On Cannabidiol Treatment for Drug-Resistant Seizures in Tuberous Sclerosis Complex. A Placebo-Controlled Randomized Clinical Trial Elizabeth A. Thiele, MD, PhD; E. Martina Bebin, MD, MPA; Hari Bhathal, MD; Floor E. Jansen, MD; Katarzyna Kotulska, MD, PhD; John A. Lawson, BMed, PhD; Finbar J. O'Callaghan, MBChB, PhD; MichaelWong,MD, PhD; Farhad Sahebkar, MD; Daniel Checketts, MSc; Volker Knappertz, MD; for the GWPCARE6 Study Group JAMA Neurology, 2020, December 21 online, E1-E7. doi : 10.1001/jamaneurol.2020.4607 IMPORTANCE : Efficacy of cannabidiol has been demonstrated in seizures associated with Lennox-Gastaut and Dravet syndromes but appears not yet to have been established in conditions with primarily focal seizures, such as [...]
Lire la suiteBibliographie : Cannabinoïdes synthétiques et Néocannabinoïdes Dr Christian Sueur, GRECC, décembre 2020 Définitions et Usages des cannabinoïdes synthétiques : 2 - 6 Toxicologie des cannabinoïdes synthétiques : 7– 12 Cannabinoïdes synthétiques et psychose : 11 - 12 Pharmacologie des cannabinoïdes synthétiques : 13 - 16 Neurophysiologie des cannabinoïdes synthétiques : 17 -18 Analyse des cannabinoïdes synthétiques : 18 - 19 Usage médical des cannabinoïdes synthétiques : 20 – 22 Rimonabant : 21 -22
Lire la suiteBibliographie : Cannabis et Cannabinoides en Psychiatrie Docteur Christian Sueur, GRECC, décembre 2020. (4e version, décembre 2020....) 1 - Généralités : 1 - 11 2 -Cannabinoïdes et anxiété : 12 3 - Cannabidiol anxiolytique : 13 - 15 4 - Cannabidiol antipsychotique : 16 - 21 5 - Cannabinoïdes et dépression : 22 - 28 6 - Cannabidiol antidépresseur : 29 7 - Cannabinoïdes et Sommeil : 30 - 31 8 - Cannabinoïdes et addiction au Cannabis : 32 - 39 9 - Cannabinoïdes et addictions (cocaine, opiacés, amphétamines, alcool, tabac) : 40 - 54 10 - Cannabinoides et syndrome de Gilles de la Tourette : 58 - 59 11 - Cannabinoides et Hyperactivité [...]
Lire la suiteThe potential synergistic effects between psychedelic administration and nature contact for the improvement of mental health Sam Gandy, Matthias Forstmann, Robin Lester Carhart-Harris, Christopher Timmermann, David Luke and Rosalind Watts Health Psychology Open, 2020, 1–21 Doi : 10.1177/2055102920978123 Abstract Therapeutic psychedelic administration and contact with nature have been associated with the same psychological mechanisms : decreased rumination and negative affect, enhanced psychological connectedness and mindfulness related capacities, and heightened states of awe and transcendent experiences, all processes linked to improvements in mental health amongst clinical and healthy populations. Nature-based settings can have inherently psychologically soothing properties which may complement all stages of psychedelic therapy (mainly [...]
Lire la suiteEffects of external stimulation on psychedelic state neurodynamics Pedro A.M. Mediano, Fernando E. Rosas, Christopher Timmermann, Leor Roseman, David J. Nutt, Amanda Feilding, Mendel Kaelen, Morten L. Kringelbach, Adam B. Barretti, Anil K. Seth, Suresh Muthukumaraswamy, Daniel Bor, and Robin L. Carhart-Harris bioRxiv preprint, 2020 doi : 10.1101/2020.11.01.356071 Abstract Recent findings have shown that psychedelics reliably enhance brain entropy (understood as neural signal diversity), and this effect has been associated with both acute and long-term psychological outcomes such as personality changes. These findings are particularly intriguing given that a decrease of brain entropy is a robust indicator of loss of consciousness (e.g. from wakefulness to [...]
Lire la suiteTroubles anxieux : le CBD peut soulager les symptômes Kalapa Clinic, Barcelone, Espagne By Gesa|30/06/2020 La peur est une réaction naturelle à certaines situations et à certains événements. Elle remplit à la fois une fonction d’avertissement et de protection. Lors d’un trouble anxieux, cependant, elle développe une dynamique propre qui est très stressante pour les personnes concernées. Diverses études et rapports d’expérience indiquent que le cannabinoïde non-psychoactif cannabidiol (CBD) peut soulager leurs symptômes. En Allemagne, le trouble anxieux est la maladie mentale la plus courante, devançant même la dépression. Environ 12 millions de personnes sont touchées, les femmes plus souvent que les hommes (1). Le [...]
Lire la suiteEarly phytocannabinoid chemistry to endocannabinoids and beyond Raphael Mechoulam, Lumír O. Hanuš, Roger Pertwee and Allyn C. Howlett NATURE REVIEWS | NEUROSCIENCE, 2014, 15, 757-764. Doi : 10.1038/nrm3811 Abstract Isolation and structure elucidation of most of the major cannabinoid constituents — including Δ9-tetrahydrocannabinol (Δ9-THC), which is the principal psychoactive molecule in Cannabis sativa — was achieved in the 1960s and 1970s. It was followed by the identification of two cannabinoid receptors in the 1980s and the early 1990s and by the identification of the endocannabinoids shortly thereafter. There have since been considerable advances in our understanding of the endocannabinoid system and its function in the [...]
Lire la suiteUse of Genetically Informed Methods to Clarify the Nature of the Association Between Cannabis Use and Risk for Schizophrenia Nathan A. Gillespie, Kenneth S. Kendler JAMA Psychiatry, Published online November 4, 2020 Cohort studies and meta-analyses have documented a robust association between cannabis use, heavy use, and misuse with future risk of schizophrenia.1-3 Despite adjusting for covariates, including current psychotic symptoms, other psychopathology, and social integration,(1) the ability of these models to determine the degree to which cannabis causes schizophrenia is limited and dependent on their ability to capture all relevant confounders. When evaluating efforts to reduce cannabis use as a means of [...]
Lire la suitePsychedelics as a Treatment for Alzheimer’s Disease Dementia Simon Andrew Vann Jones and Allison O’Kelly Cornwall Partnership NHS Foundation Trust, Liskeard, United Kingdom Frontiers in Synaptic Neuroscience, August 2020 | Volume 12 | Article 34 doi : 10.3389/fnsyn.2020.00034 Currently, there are no disease-modifying treatments for Alzheimer’s disease (AD) or any other dementia subtype. The renaissance in psychedelic research in recent years, in particular studies involving psilocybin and lysergic acid diethylamide (LSD), coupled with anecdotal reports of cognitive benefits from micro-dosing, suggests that they may have a therapeutic role in a range of psychiatric and neurological conditions due to their potential to stimulate neurogenesis, provoke neuroplastic [...]
Lire la suiteRole of the endogenous cannabinoid system in nicotine addiction : novel insights Islam Hany Gamaleddin, Jose M.Trigo, Aliou B. Gueye, Alexander Zvonok, Alexandros Makriyannis, Steven R. Goldberg and Bernard Le Foll Frontiers in Psychiatry, 2015, Vol 6, Article 41, 1-12. doi : 10.3389/fpsyt.2015.00041 Several lines of evidence have shown that the endogenous cannabinoids are implicated in several neuropsychiatric diseases. Notably, preclinical and human clinical studies have shown a pivotal role of the cannabinoid system in nicotine addiction. The CB1 receptor inverse agonist/antagonist rimonabant (also known as SR141716)was effective to decrease nicotine-taking and nicotine-seeking in rodents, as well as the elevation of dopamine induced by [...]
Lire la suite